Table 1.
Summary of top differentially regulated pathways between fimbria versus ampulla using Ingenuity Pathway Analysis. Gene list for each pathway can be found in Dataset S2.
| Top Canonical Pathways by Phase | p-Value | Overlap of Curated Genes in Pathway |
| Antigen Presentation Pathway | 4.81 × 10−23 | 73.5% (25/34) |
| Allograft Rejection Signaling | 2.28 × 10−16 | 55.0% (22/40) |
| OX40 (T-cell survival) Signaling Pathway | 4.0 × 10−13 | 43.8% (21/48) |
| Autoimmune Thyroid Disease Signaling | 3.6 × 10−12 | 47.4% (18/38) |
| T Helper Cell Differentiation | 6.43 × 10−12 | 35.4% (23/65) |
| Top Canonical Pathways by Anatomy | p-Value | Overlap |
| Role of Oct4 in Mammalian Embryonic Stem Cell Pluripotency | 0.00555 | 51.1% (23/45) |
| Cellular Effects of Sildenafil | 0.00823 | 42.4% (53/125) |
| Planar Cell Polarity Pathway | 0.00983 | 46.8% (29/62) |
| Vitamin D Receptor /Retinoid X Receptor Activation | 0.0124 | 44.7% (34/76) |
| GDP Mannose Biosynthesis | 0.0144 | 83.3% (5/6) |
| NRF2-mediated Oxidative Stress Response | 0.0219 | 39% (73/187) |
| Top Toxicology Pathways by Anatomy | p-Value | Overlap |
| CAR/RXR Activation | 0.00262 | 58.6% (17/29) |
| VDR/RXR Activation | 0.0124 | 44.7% (34/76) |
| NRF2-mediated Oxidative Stress Response | 0.0436 | 37.6% (80/213) |
| Acute Renal Failure Panel (Rat) | 0.0439 | 43.6% (24/55) |